• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

Johnson & Johnson Ordered to Pay $70 Million to California Woman For Cancer-Linked Baby Powder

Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
October 28, 2016, 12:12 PM ET
LS010183
Photograph by Nancy R. Cohen — Getty Images

Johnson & Johnson has lost its third lawsuit alleging that the pharmaceutical company’s baby powder causes ovarian cancer.

Jurors in St. Louis awarded Deborah Giannecchini $70 million late Thursday, according to Bloomberg. For 40 years, Giannecchini, 62, had used the talcum powder for feminine hygiene, but stopped when she was diagnosed with ovarian cancer three years ago. Now her lawyers say Giannecchini has an 80% chance of dying in the next two years, despite having undergone extensive treatment.

Carol Goodrich, a spokesperson for Johnson & Johnson, says the company will appeal to the decision.

“We deeply sympathize with the women and families impacted by ovarian cancer,” she said. “We will appeal today’s verdict because we are guided by the science, which supports the safety of Johnson’s Baby Powder.”

Additionally, research into the link between talc and cancer have been been mixed or inconclusive, according to the American Cancer Society.

That likely factored into a New Jersey judge’s decision to throw out two lawsuits against Johnson in Johnson in September, which alleged that the company’s talcum powder had caused their ovarian cancer.

Johnson & Johnson is also appealing two other similar lawsuits in which it was ordered to pay $72 million and $55 million. Johnson & Johnson has been roped in to some 1,700 lawsuits in state and federal courts alleging that the company ignored research suggesting that its talc-based products increased the chance of ovarian cancer, and failed to inform consumers.

Giannecchini’s claims that Johnson & Johnson was shown “30 years of studies” that the talc-based powders increased the risk of ovarian cancer.

 

Johnson & Johnson has been ordered to pay $65 million to Giannecchini in punitive damages and nearly $2.5 million for her medical bills, pain, and suffering. Co-defendent, Imerys Talc America, which supplied the talc, has been orderded to pay $2.5 million in punitive damages.

About the Author
Lucinda Shen
By Lucinda Shen
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

PoliticsModerna
FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection
By Lauran Neergaard and The Associated PressFebruary 18, 2026
2 hours ago
Healthsleep
The 4 Best Bed Frames of 2026: Expert Tested
By Christina SnyderFebruary 18, 2026
5 hours ago
Successthe future of work
As boomer and Gen X bosses retire, working from home will make a major comeback, new research predicts—and you have work-life balance loving Gen Z to thank
By Orianna Rosa RoyleFebruary 17, 2026
1 day ago
HealthHealth
Confronting Asia’s growing rate of chronic conditions means tackling cultural issues as much as medical ones
By Stuart A. SpencerFebruary 15, 2026
3 days ago
Susan Blumenthal
AICancer
Meet the American spies who helped mammograms save more lives
By Erik GermanFebruary 15, 2026
3 days ago
HealthDietary Supplements
5 Best Nootropics of 2026: Expert Reviewed Supplements
By Christina SnyderFebruary 13, 2026
5 days ago

Most Popular

placeholder alt text
AI
Thousands of CEOs just admitted AI had no impact on employment or productivity—and it has economists resurrecting a paradox from 40 years ago
By Sasha RogelbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
You need $2 million to retire and 'almost no one is close,' BlackRock CEO warns, a problem that Gen X will make 'harder and nastier'
By Sydney LakeFebruary 17, 2026
1 day ago
placeholder alt text
Economy
$56 trillion national debt leading to a spiraling crisis: Budget watchdog warns the U.S. is walking a crumbling path
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Economy
Trump crackdown drives 80% plunge in immigrant employment, reshaping labor market, Goldman says
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, February 17, 2026
By Joseph HostetlerFebruary 17, 2026
1 day ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
7 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.